Tango Therapeutics (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$20.50
▼(-23.05% Downside)
Action:Reiterated
Date:05/16/26
Overall score is held back primarily by weak financial performance (large losses and significant cash burn despite strong gross margins), with only partial support from a strong balance sheet. Technicals are moderately constructive but mixed, while valuation is constrained by negative earnings and no dividend support. Corporate events are mildly positive due to leadership strengthening and late-stage clinical focus.
Positive Factors
Balance-sheet strength
Very low leverage and meaningful equity provide durable financial flexibility for a clinical-stage biotech. This reduces immediate refinancing pressure, allows multi-year R&D funding decisions, and strengthens bargaining power with partners during pivotal development and potential commercialization planning.
Negative Factors
Heavy ongoing cash burn
Sustained negative operating and free cash flow at this scale creates persistent financing needs; absent successful exits or partner funding, the company may face dilution or restrictive financing terms. Large burn increases execution risk for late-stage trials and long-term capital efficiency concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Very low leverage and meaningful equity provide durable financial flexibility for a clinical-stage biotech. This reduces immediate refinancing pressure, allows multi-year R&D funding decisions, and strengthens bargaining power with partners during pivotal development and potential commercialization planning.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.97B
Dividend YieldN/A
Average Volume (3M)3.04M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth39.04%
EPS Growth32.40%
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding144,647,980
10 Day Avg. Volume3,795,201
30 Day Avg. Volume3,037,748
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue39.72
Enterprise Value/Gross Profit40.50
Enterprise Value/Ebitda-19.90
Forecast
1Y Price Target
$30.70Price Target Upside15.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$6.66M
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as...
How the Company Makes Money
As a clinical-stage biotechnology company, Tango Therapeutics primarily generates revenue from collaboration and licensing arrangements rather than from product sales, because it does not have broadly available commercial drugs on the market. Its ...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.99M | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 55.89M | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -113.72M | -109.01M | -143.10M | -111.76M | -109.46M | -57.29M |
| Net Income | -107.23M | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | ||||||
| Total Assets | 435.79M | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 379.84M | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 32.79M | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 44.29M | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 391.51M | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | ||||||
| Free Cash Flow | -142.54M | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -141.55M | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -61.83M | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 302.34M | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Positive
26.64
Price Trends
17.02
Positive
13.68
Positive
10.47
Positive
Market Momentum
2.19
Negative
77.42
Negative
94.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 26.64 is above the 20-day moving average (MA) of 21.21, above the 50-day MA of 17.02, and above the 200-day MA of 10.47, indicating a bullish trend. The MACD of 2.19 indicates Negative momentum. The RSI at 77.42 is Negative, neither overbought nor oversold. The STOCH value of 94.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $3.74B | -21.26 | -25.30% | ― | ― | 54.61% | |
52 Neutral | $737.28M | -3.29 | -100.29% | ― | 1.92% | -1130.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.97B | -16.50 | -50.30% | ― | 39.04% | 32.40% | |
48 Neutral | $494.68M | -3.01 | -36.48% | ― | ― | ― | |
47 Neutral | $1.46B | -4.88 | -39.69% | ― | -72.09% | -754.83% | |
42 Neutral | $529.21M | -3.14 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
TNGX
Tango Therapeutics
20.56
19.06
1270.67%
ORKA
Oruka Therapeutics
61.93
51.87
515.61%
IMTX
Immatics
10.87
6.13
129.32%
SPRY
ARS Pharmaceuticals
7.43
-6.18
-45.40%
PRME
Prime Medicine, Inc.
2.93
1.34
84.28%
UPB
Upstream Bio, Inc.
9.09
0.45
5.21%
Tango Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Tango Therapeutics Reshapes Board Amid Late-Stage Progress
Positive
May 13, 2026
On May 12, 2026, Tango Therapeutics announced that directors Alexis Borisy and Kanishka Pothula resigned from the board, effective May 13, 2026, with no disagreements cited over company practices. Sung Lee was appointed Lead Independent Director, ...
Executive/Board Changes
Tango Therapeutics Finalizes Separation Agreement with Former CFO
Neutral
May 8, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer and principal financial officer Daniella Beckman would leave her roles, effective April 15, 2026, with her last day of employment recorded as May 1, 2026. On M...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push
Positive
Apr 15, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer Daniella Beckman would depart her roles effective April 15, 2026, and appointed veteran biotech finance executive Matthew Gall as CFO and principal financial o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.